Phase 3 randomized controlled study of gastroretentive gabapentin for the treatment of moderate-to-severe hot flashes in menopause

Menopause

Volumn 21, Issue 6, 2014, Pages 567-573

  Pinkerton, Joann V ^a   Kagan, Risa ^b   Portman, David ^c   Sathyanarayana, Rekha ^d   Sweeney, Michael ^d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b Sutter East Bay Medical Foundation   (United States)

^c Columbus Center for Women's Health Research ^*  (United States)

^d Depomed Inc   (United States)

Author keywords

Clinical meaningfulness.; Gabapentin; Gastroretentive; Hot flashes; Menopause; Vasomotor symptoms

Indexed keywords

GABAPENTIN; PLACEBO; 4 AMINOBUTYRIC ACID; AMINE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; DELAYED RELEASE FORMULATION;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; HEADACHE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SLEEP; SOMNOLENCE; TREATMENT OUTCOME; CHEMICALLY INDUCED; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; HOT FLASHES; MIDDLE AGED; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; AMINES; CALCIUM CHANNEL BLOCKERS; CYCLOHEXANECARBOXYLIC ACIDS; DELAYED-ACTION PREPARATIONS; DISORDERS OF EXCESSIVE SOMNOLENCE; DIZZINESS; DOUBLE-BLIND METHOD; FEMALE; GAMMA-AMINOBUTYRIC ACID; HOT FLASHES; HUMANS; MENOPAUSE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84901610440     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0b013e3182a7c073     Document Type: Article

References (27)

1. Bachmann GA. Vasomotor flushes in menopausal women. Am J Obstet Gynecol 1999;180:S312-S316.
2. Morrissey DR, Kirchner JT. Management of the climacteric. Options abound to relieve women's midlife symptoms. Postgrad Med 2000;108: 85-88, 93-94, 97-100.
3. Oldenhave A, Jaszmann LJ, Haspels AA, Everaerd WT. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol 1993;168:772-780.
4. Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003;101:337-345.
5. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebocontrolled trial. Lancet 2005;366:818-824.
6. Butt DA, Lock M, Lewis JE, Ross S, Moineddin R. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause 2008;15:1-9.
7. Guttuso T Jr. Hot flashes refractory to HRT and SSRI therapy but responsive to gabapentin therapy. J Pain Symptom Manage 2004;27: 274-276.
8. Reddy SY, Warner H, Guttuso T Jr, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006;108:41-48.
9. NeurontinA (gabapentin) Capsules, NeurontinA (gabapentin) Tablets, NeurontinA (gabapentin) Oral Solution [US prescribing information]. New York, NY: Pfizer Inc; 2012. Available at: http://labeling.pfizer.com/ShowLabeling. aspx?id=630. Accessed July 18, 2012.
10. Argoff CE, Chen C, Cowles VE. Clinical development of a once-daily gastroretentive formulation of gabapentin for treatment of postherpetic neuralgia: an overview. Expert Opin Drug Deliv 2012;9:1147-1160.
11. Hou SY, Cowles VE, Berner B. Gastric retentive dosage forms: a review. Crit Rev Ther Drug Carrier Syst 2003;20:459-497.
12. Berner B, Cowles VE. Case studies in swelling polymeric gastric retentive tablets. Expert Opin Drug Deliv 2006;3:541-548.
13. Gordi T, Hou E, Kasichayanula S, Berner B. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive, extended-release, and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects. Clin Ther 2008;30:909-916.
14. Sang CN, Sathyanarayana R, Sweeney M. Gastroretentive gabapentin (G-GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN). Clin J Pain 2013;29:281-288.
15. Sweeney M, Sathyanarayana R, Gordi T, Cowles VE, Heritier M. Positive efficacy data from a phase 2 trial of gabapentin extended-release in the treatment of menopausal hot flashes [Abstract]. Menopause 2008;15: 1225. Abstract P-61 16.
16. Kagan R, Sathyanarayana R, Sweeney M, Pratt J, Zheng Y. The effect of outliers on hot flash frequency in the Breeze 1 Study of gabapentin-ER for the non-hormonal treatment of vasomotor symptoms [Abstract]. Menopause 2010;17:1219. Abstract S-14.
17. Baron M, Cowles VE, Utian W, Koltun W, Sathyanarayana R, Sweeney M. Efficacy of gabapentin extended-release (G-ER) on vasomotor symptoms in post-menopausal women in Breeze 2 Study [Abstract]. Menopause 2011;18:1369. Abstract P-76 18.
18. Stokes ME, Davis CS, Koch GG. Categorical Data Analysis Using the SAS System, 2nd ed. Cary, NC: SAS Institute Inc, 2000.
19. Center for Drug Evaluation and Research. Guidance for Industry: Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy SymptomsVRecommendations for Clinical Evaluation. Rockville, MD: Food and Drug Administration, 2003. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071643.pdf. Accessed May 31, 2013.
20. Ohayon MM. Severe hot flashes are associated with chronic insomnia. Arch Intern Med 2006;166:1262-1268.
21. Regestein QR. Hot flashes, sleep, and mood. Menopause 2010;17:16-18.
22. Cowles VE, Gordi T, Hou SY. Steady-state pharmacokinetics of gabapentin after administration of a novel gastroretentive extendedrelease formulation in postmenopausal women with vasomotor symptoms. Clin Drug Investig 2012;32:593-601.
23. Angeliq [US prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals; 2012. Available at: http://berlex.bayerhealthcare.com/html/ products/pi/fhc/Angeliq-PI.pdf. Accessed May 31, 2013.
24. Bland JM, Altman DG. Regression towards the mean. BMJ Open 1994;308:1499.
25. Mahon SM, Kaplan M. Placebo effect in hot flush research. Lancet Oncol 2012;13:e188.
26. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003;2:473-481.
27. Simon JA, Sanacora G, Bhaskar S, Lippman J. Safety and efficacy of low-dose mesylate salt of paroxetine (LDMP) for the treatment of vasomotor symptoms (VMS) associated with menopause: a 24-week, randomized, placebo controlled phase 3 study [Abstract]. Menopause 2012;19:1371. Abstract S-2.